Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...
Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...
According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...
Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...
About LP-310 LP-310 is an innovative oral rinse formulation of LP-10 (tacrolimus), developed to address OLP. Designed to provide localized therapeutic effects while minimizing systemic exposure, ...
Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...
Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...
Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback